ERBIN Activators
ERBIN activators encompass a diverse class of chemicals that influence various cellular signaling pathways, thereby modulating the activity of ERBIN. The chemicals in this class act primarily by targeting key components of pathways like MAPK/ERK, PI3K/AKT, mTOR, AMPK, and others, which intersect with ERBIN's functional sphere. These activators, including MEK inhibitors like U0126, Trametinib, and PD98059, p38 MAPK inhibitors such as SB203580 and BIRB 796, PI3K inhibitors like LY294002 and Wortmannin, an mTOR inhibitor Rapamycin, and an AMPK inhibitor Dorsomorphin, play crucial roles in modulating the signaling cascades that are central to ERBIN's involvement in cellular processes.
Each of these chemicals alters specific components within their targeted pathways, leading to a cascade of effects that can indirectly influence ERBIN. For instance, MEK inhibitors disrupt the MAPK/ERK pathway, pivotal for cellular growth and differentiation, which can lead to changes in ERBIN's activity or expression. Similarly, PI3K inhibitors modulate the PI3K/AKT pathway, integral to cell survival and metabolism, potentially impacting ERBIN's role in these processes. Forskolin, with its unique mechanism of activating adenylate cyclase and increasing cAMP levels, demonstrates the diverse mechanisms through which these activators operate.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Another MEK inhibitor, PD98059 specifically blocks the MAPK/ERK pathway. This can influence ERBIN indirectly, as this pathway is associated with ERBIN's signaling functions. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that can affect ERBIN through its influence on the MAPK pathway. By inhibiting p38, SB203580 could modulate the interaction or function of ERBIN in cells. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that indirectly affects ERBIN by modulating the PI3K/AKT pathway, which intersects with pathways associated with ERBIN. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor, Wortmannin, can alter the PI3K/AKT pathway, potentially influencing ERBIN's activity or expression indirectly. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, Rapamycin can affect ERBIN indirectly through the mTOR signaling pathway, which is linked to various cellular processes that ERBIN may be involved in. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
A MEK inhibitor with a potential indirect effect on ERBIN through the MAPK/ERK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, another member of the MAPK family, SP600125 can indirectly influence ERBIN by altering JNK pathway signaling. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, leading to increased cAMP levels, which can indirectly influence ERBIN through various cAMP-dependent pathways. | ||||||
Dorsomorphin dihydrochloride | 1219168-18-9 | sc-361173 sc-361173A | 10 mg 50 mg | $186.00 $751.00 | 28 | |
An AMPK inhibitor, Dorsomorphin can indirectly affect ERBIN by altering AMPK pathway signaling. | ||||||
Doramapimod | 285983-48-4 | sc-300502 sc-300502A sc-300502B | 25 mg 50 mg 100 mg | $149.00 $281.00 $459.00 | 2 | |
A p38 MAPK inhibitor that can indirectly influence ERBIN through its effects on the MAPK pathway. | ||||||